Právní předpis byl sestaven k datu 09.02.2026.
Zobrazené znění právního předpisu je účinné od 29.12.2023.
Sdělení Ministerstva zdravotnictví o antigenním složení očkovacích látek pro pravidelná, zvláštní a mimořádná očkování pro rok 2024
420/2023 Sb.
420
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxxx
xx xxx 19. xxxxxxxx 2023
x xxxxxxxxxx složení očkovacích xxxxx xxx xxxxxxxxxx, xxxxxxxx x xxxxxxxxx xxxxxxxx xxx xxx 2024
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxxx xxxxx §80 xxxx. 1 xxxx. x) xxxxxx x. 258/2000 Xx., x xxxxxxx veřejného xxxxxx x x xxxxx některých xxxxxxxxxxxxx xxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxx, xxxxxxx xx xxxxxxx doporučení Xxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx xxx pravidelná, xxxxxxxx x mimořádná xxxxxxxx xxx xxx 2024:
1.&xxxx;Xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxxx
1x)&xxxx;xxxxxxxxxxx očkovací látka xxxxx xxxxxxx, dávivému xxxxx (xxxxxxxxxx xxxxx), xxxxxx, xxxxxx xxxxxxxx xxxxx (xxxxxxxxxxxx xxxxx), xxxxxx xxxxxxxxxx B, xxxxxxx xxxxxxxxx Xxxxxxxxxxx xxxxxxxxxx typ x (XXxXXxxXXXXXX)
Xx xxxxxxxxxxxx 1 xxxxx (0,5 ml) xxxxxxxx:
Xxxxxxxxxxx anatoxinum1 ne xxxx xxx 30 mezinárodních xxxxxxxx (XX)
Xxxxxx xxxxxxxxxx1&xxxx;xx xxxx xxx 40 xxxxxxxxxxxxx jednotek (IU)
Antigeny Xxxxxxxxxx xxxxxxxxx:
Xxxxxxxxx xxxxxxxxxx (XX)1&xxxx;25 xxxxxxxxxx
Xxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxx (FHA)1 25 xxxxxxxxxx
Xxxxxxxxxxx (XXX)1&xxxx;8 mikrogramů
Antigenum tegiminis xxxxxxxxxxx X (HBs)2,3 10 xxxxxxxxxx
Xxxxx xxxxxxxxxxxxxxx inactivatum (XXX)
xx xxx 1 (xxxx Mahoney)4 40 X xxxxxxxx xxxxxxxx
xxxxx 2 (xxxx XXX-1)4&xxxx;8 X xxxxxxxx xxxxxxxx
xxxxx 3 (xxxx Xxxxxxx)4&xxxx;32 X xxxxxxxx xxxxxxxx
Xxxxxxxxxxx influenzae xxxxx b xxxxxxxxxxxxxxx
(Xxxxxxxxxxxxxxxxxxx xxxxxxxx) 10 mikrogramů
conj. xxx xxxxxx. tetanico xxxx nosný xxxxxxx xxxxxxxxx 25 xxxxxxxxxx
1&xxxx;xxxxxxxxxxx xx xxxxxxxx xxxxxxx, xxxxxxxxxxx (Xx(XX)3) 0,5 xxxxxxxxx Xx3+
2&xxxx;xxxxxxxx xxxxxxxxxxxxx XXX xxxxxxxxxxx xx xxxxxxx xxxxxxxxxxxx xxxxx (Xxxxxxxxxxxxx xxxxxxxxxx)
3&xxxx;xxxxxxxxxxx xx xxxxxxxxxxx xxxxxxx (XxXX4) 0,32 miligramů Xx3+
4&xxxx;xxxxxxxxx xx VERO xxxxxxx
XXXX
1xx)&xxxx;xxxxxxxxxxx xxxxxxxx látka xxxxx xxxxxxx, xxxxxxxx kašli (xxxxxxxxxx forma), xxxxxx, xxxxxx přenosné obrně (xxxxxxxxxxxx xxxxx), xxxxxx xxxxxxxxxx X, nákazám xxxxxxxxx Xxxxxxxxxxx influenzae xxx x (XXxXXxxXXXXXX)
Xxxxx xxxxx1&xxxx;(0,5 xx) xxxxxxxx:
Xxxxxxxxxxx xxxxxxxxxx xx méně xxx 20 xxxxxxxxxxxxx xxxxxxxx (XX)2
Xxxxxx xxxxxxxxxx xx xxxx xxx 40 mezinárodních jednotek (XX)2
Xxxxxxxx Xxxxxxxxxx xxxxxxxxx
Xxxxxxxxx xxxxxxxxxx 25 xxxxxxxxxx
Xxxxxxxxxxxxxx xxxxxxxxxxxx 25 xxxxxxxxxx
Xxxxx Xxxxxxxxxxxxxxx (xxxxxxxxxxxx)3
xxxxx 1 (Xxxxxxx) 40 X xxxxxxxx xxxxxxxx4
xx xxx 2 (XXX-1) 8 X xxxxxxxx xxxxxxxx4
xxxxx 3 (Saukett) 32 X jednotek antigenu4
Antigenum xxxxxxxxx hepatitidis X5&xxxx;10 xxxxxxxxxx
Xxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx X 12 xxxxxxxxxx
(Xxxxxxxxxxxxxxxxxxx xxxxxxxx)
xxxxxxxxx xxx xxxxxx anatoxinum 22-36 xxxxxxxxxx
1&xxxx;xxxxxxxxxxx xx hydratovaný xxxxxxxx hlinitý (0,6 xx Al3+)
2 jako spodní xxx xxxxxxxxxxxxx (p = 0,95)
3&xxxx;xxxxxxxxx xx XXXX buňkách
4 nebo xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx
5&xxxx;xxxxxxxx xxxxxxxxxxxxx DNA xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx Xxxxxxxxx polymorpha
NEBO
1ab) Vakcína proti xxxxxxx, xxxxxx, xxxxxxxx xxxxx (acelulární xxxxxxxxxx), xxxxxxxxxx X (xXXX), xxxxxx xxxxxxxx obrně (xxxxxxxxxxxx) a konjugovaná xxxxxxx xxxxx Xxxxxxxxxxx xxxx x (adsorbovaná)
Jedna xxxxx (0,5 ml) xxxxxxxx:
Xxxxxxxxxxx xxxxxxxxxx1&xxxx;xx méně xxx 20 XX
Xxxxxx xxxxxxxxxx1&xxxx;xx xxxx xxx 40 XX
Xxxxxxxx Xxxxxxxxxxx xxxxxxxx1
Xxxxxxxxx xxxxxxxxxx (PT) 20 xxxxxxxxxx
Xxxxxxxxxxxxxxx xxxxxxxxxxxx (XXX) 20 mikrogramů
Pertactinum (XXX) 3 xxxxxxxxxx
Xxxxxxxx xxxx 2 xx 3 (FIM) 5 xxxxxxxxxx
Xxxxxxxxx xxxxxxxxx xxxxxxxxxxx X&xxxx;2,3&xxxx;10 xxxxxxxxxx
Xxxxx poliomyelitidis (xxxxxxxxxxx)4
Xxxxx 1 (Xxxxxxx) 40 X xxxxxxxx xxxxxxxx5
Xxxxx 2 (XXX-1) 8 X xxxxxxxx xxxxxxxx5
Xxxxx 3 (Saukett) 32 X xxxxxxxx xxxxxxxx5
Xxxxxxxxxxxxxx Haemophili xxxxxxxxxx xxxxx x
(Xxxxxxxxxxxxxxxxxxx xxxxxxxx) 3 mikrogramy xxxxxxxxxx xxx xxxxxxxxx meningococci xxxxx b2 50 xxxxxxxxxx
1&xxxx;xxxxxxxxxxx xx fosforečnan xxxxxxx (0,17 xx Xx3+)
2&xxxx;xxxxxxxxxxx xx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxx (0,15 xx Xx3+)
3&xxxx;xxxxxxxx xxxxxxxxxxxxx XXX xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx
4&xxxx;xxxxxxxxx na Xxxx xxxxxxx
5&xxxx;xxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1x)&xxxx;xxxxxxxx xxxxx xxxxx záškrtu, xxxxxxxx xxxxx (xxxxxxxxxx forma), xxxxxx (DTaP)
Jedna xxxxx (0,5 xx) xxxxxxxx xxxx léčivé xxxxx:
Xxxxxxxxxxx xxxxxxxxxx* ≥ 30 XX
Xxxxxx xxxxxxxxxx* ≥ 40 XX
Xxxxxxxxx anatoxinum* (XX) 25 xxxxxxxxxx
Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx* (XXX) 25 mikrogramů
Pertactinum* (69xX) 8 mikrogramů
* adsorbováno na xxxxxxxx xxxxxxx xxxxxx: 0,5 xxxxxxxxx
XXXX
1xx)&xxxx;Xxxxxxxx xxxxx xxxxx xxxxxxx, xxxxxx x dávivému xxxxx (xxxxxxxxxx) xx xxxxxxxx xxxxxxx antigenů (Tdap)
Jedna xxxxx (0,5 xx) xxxxxxxx:
Xxxxxxxxxxx xxxxxxxxxx - Xxxxxxxxx 2 IU* (2 Xx)
Xxxxxx anatoxinum - Xxxxxxxxx 20 XX* (5 Xx)
Xxxxxxxxx xxxxxxxx
Xxxxxxxxx xxxxxxxxxx - 2,5 mikrogramu
Haemagglutinum xxxxxxxxxxxx - 5 xxxxxxxxxx
Xxxxxxxxxxx - 3 xxxxxxxxxx
Xxxxxxxx, xxxx 2 et 3 - 5 xxxxxxxxxx
Xxxxxxxxxxx xx xxxxxxxxxxx xxxxxxx - 1,5 xx (0,33 xx xxxxxxx)
*&xxxx;Xxxx xxxxxx xxxxxxx xxxxxxxxx spolehlivosti (p = 0,95) xxxxxxxx xxxxxx xxxxx testu xxxxxxxxx v Xxxxxxxxx xxxxxxxx.
XXXX
1xx)&xxxx;Xxxxxxxx látka xxxxx xxxxxxx, tetanu a xxxxxxxx xxxxx (xxxxxxxxxx xxxxxxxxxx) xx xxxxxxxx xxxxxxx xxxxxxxx (Xxxx)
Xxxxx xxxxx (0,5 ml) xxxxxxxx:
Xxxxxxxxxxx xxxxxxxxxx1&xxxx;xx méně xxx 2 xxxxxxxxxxx xxxxxxxx (XX) (2,5 Xx)
Xxxxxx xxxxxxxxxx1&xxxx;xx xxxx xxx 20 xxxxxxxxxxxxx xxxxxxxx (IU) (5 Xx)
Xxxxxxxxxxx xxxxxxxxx xxxxxxxx:
Xxxxxxxxx xxxxxxxxxx1&xxxx;8 xxxxxxxxxx
Xxxxxxxxx haemagglutinum xxxxxxxxxxxx1&xxxx;8 xxxxxxxxxx
Xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxx1&xxxx;2,5 xxxxxxxxxx
1&xxxx;xxxxxxxxxxx xx xxxxxxxxxxx hydroxid xxxxxxx (Al(OH)3) 0,3 xxxxxxxxx Xx3+&xxxx;x xxxxxxxxxxx xxxxxxx (XXXX4) 0,2 xxxxxxxxx Al3+
1c) očkovací xxxxx xxxxx nákazám xxxxxxxxx Xxxxxxxxxxx xxxxxxxxxx typ x:
Xxxxx dávka lyofilizované xxxxxxx xxxxxxxx:
Xxxxxxxxxxxxxxx Xxx xxxxxxxxxxx (10 xxxxxxxxxx) xxx Anatoxino xxxxxxxx (xxxxxxxxx 25 xxxxxxxxxx).
1x)&xxxx;xxxxxxxx xxxxx proti xxxxxx:
Xxxxx xxxxx xxxxxxxx:
Xxxxxx xxxxxxxxxx - xxx. 40 xxxxxxxxxxxxx jednotek
1e) očkovací xxxxx xxxxx xxxxxx xxxxxxxxxx X x xxxxxx xxxxxxx:
Xxxxx xxxxx xxxxxxxx:
Xxxxxxxxx xxxxxxxxx xxxxxxxxxxx B - 10 mikrogramu
1f) očkovací xxxxx xxxxx xxxxxx xxxxxxxxxx X x xxxxxxx xxxxxxx
Xxxxx xxxxx xxxxxxxx:
Xxxxxxxxx xxxxxxxxx xxxxxxxxxxx X - 20 xxxxxxxxxx
1x)&xxxx;xxxxxxxx xxxxx xxxxx xxxxxxxxxx, příušnicím x xxxxxxxxx:
Xxxxx xxxxx obsahuje:
Morbillorum xxxxx xxxxxxxxxx1&xxxx;(Xxxxxxx) xxx. 103,0&xxxx;xxxxxxxx xxxxx xxx xxxxxxxx xxxxxxx503
Xxxxxxxxxxx virus xxxxxxxxxx1&xxxx;(XXX 4385) min. 103,7&xxxx;xxxxxxxx xxxxx xxx xxxxxxxx kulturu503
Rubeolae virus xxxxxxxxxx2&xxxx;(Xxxxxx RA 27/3) xxx. 103,0 infekční dávka xxx buněčnou kulturu503
1 pomnoženo xx xxxxxxx xxxxxxxx xxxxxx
2&xxxx;xxxxxxxxx xx xxxxxxxx xxxxxxxxxxx xxxxxxx (MRC-5)
3 50% xxxxxxxx xxxxx tkáňové xxxxxxx
XXXX
1xx)&xxxx;xxxxxxxx xxxxx proti xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxx
Xx rozpuštění obsahuje xxxxx xxxxx (0,5 xx):
Xxxxx xxxxxxxxxxx1&xxxx;xxxxx xxxxxxxxxx (xxxx Xxxxxx’ Xxxxxxxxx) xx xxxx xxx 1x103&xxxx;XXXX50*
Xxxxx parotitidis1 vivum attenuatum (xxxx Jeryl Lynn™, xxxxxxx X) xx xxxx než 12,5x103 CCID50*
Virus xxxxxxxx2&xxxx;xxxxx xxxxxxxxxx (xxxx Xxxxxx XX 27/3) xx méně xxx 1x103&xxxx;XXXX50*
*&xxxx;50% xxxxxxxx dávka xxxxxxx xxxxxxx
1&xxxx;xxxxxxxx xx xxxxxxx xxxxxxxx embryí.
2 vyrobeno xx xxxxxxxx xxxxxxxxxxx xxxxxxxx XX-38 xxxxxxxxxxxxx.
1x)&xxxx;xxxxxxxx xxxxx proti dětské xxxxxxxx xxxxx x xxxxxxxxxxxx xxxxx:
Xxxxx xxxxx xxxxxxxx:
Xxxxx poliomyelitis xxxxxxxxxxx xxxxx 1 (Xxxxxxx) ..... 40 xxxxxxxxxxx X jednotek*
Virus poliomyelitis xxxxxxxxxxx typus 2 (XXX-1) .......... 8 xxxxxxxxxxx X jednotek*
Virus xxxxxxxxxxxxx xxxxxxxxxxx typus 3 (Xxxxxxx) ........ 32 xxxxxxxxxxx D xxxxxxxx*
*&xxxx;xxxx množství xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxxxxx metody.
1ch) očkovací xxxxx xxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxxxxx schématu:
1cha) konjugovaná očkovací xxxxx xxxxxxxx:
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 1l 2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx polysaecharidum xxxxxxxxx 31&xxxx;2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 41&xxxx;2,2 μg
Streptococci xxxxxxxxxx xxxxxxxxxxxxxxx sérotypus 51 2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 6X1&xxxx;2,2 μg
Streptococci xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 6X1&xxxx;4,4 μg
Streptococci xxxxxxxxxx xxxxxxxxxxxxxxx sérotypus 7F1 2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 9X1&xxxx;2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 141&xxxx;2,2 μg
Streptococci xxxxxxxxxx xxxxxxxxxxxxxxx sérotypus 18X1&xxxx;2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx 19A1 2,2 μx
Xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxx sérotypus 19X1&xxxx;2,2 μx
Xxxxxxxxxxxx pneumoniae xxxxxxxxxxxxxxx xxxxxxxxx 23X1&xxxx;2,2 μx
1 Xxxxxxxxxx s xxxxxx proteinem XXX197 x xxxxxxxxxx na xxxxxxxxxxx xxxxxxx (0,125 xx xxxxxxx).
X
1xxx)&xxxx;xxxxx xxxxxxxxxxxxx xxxxxxxx
xx 25 mikrogramech xxxxxxxxxxxxx 23 xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx sérotypů: 1, 2, 3, 4, 5, 6B, 7X, 8, 9N, 9V, 10X, 11A, 12F, 14, 15X, 17X, 18X, 19X, 19X, 20, 22X, 23F, 33X.
XXXX
1xxx)&xxxx;xxxxxxxxxxx očkovací látka xxxxx xxxxxxxxxxxxx xxxxxxxx
Xxxxx xxxxx (0,5 ml) xxxxxxxx:
Xxxxxxxxxxxx xxxxxxxx (pneumokoka) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 1&xxxx;1,2&xxxx;2,2 μg
polysacharid xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 3&xxxx;1,2&xxxx;2,2 μg
polysacharid xxxxxxxx (pneumokoka) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 4&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx pneumoniae xxxxxxxx 5&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Streptococcus xxxxxxxxxx xxxxxxxx 6X&xxxx;1,2&xxxx;2,2 μg
polysacharid xxxxxxxx (xxxxxxxxxx) Streptococcus xxxxxxxxxx xxxxxxxx 6B 1,2 4,4 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 7X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 8&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx xxxxxxxxxx sérotypu 9X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx bakterie (xxxxxxxxxx) Xxxxxxxxxxxxx xxxxxxxxxx sérotypu 10X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Streptococcus pneumoniae xxxxxxxx 11X&xxxx;1,2&xxxx;2,2 μg
polysacharid xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 12X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (xxxxxxxxxx) Xxxxxxxxxxxxx pneumoniae sérotypu 14&xxxx;1,2&xxxx;2,2 μg
polysacharid bakterie (xxxxxxxxxx) Streptococcus xxxxxxxxxx xxxxxxxx 15X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (pneumokoka) Xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx 18X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx bakterie (xxxxxxxxxx) Xxxxxxxxxxxxx pneumoniae xxxxxxxx 19X&xxxx;1,2&xxxx;2,2 μg
polysacharid bakterie (xxxxxxxxxx) Xxxxxxxxxxxxx pneumoniae xxxxxxxx 19X&xxxx;1,2&xxxx;2,2 μg
polysacharid xxxxxxxx (xxxxxxxxxx) Streptococcus xxxxxxxxxx sérotypu 22X&xxxx;1,2&xxxx;2,2 μx
xxxxxxxxxxxx xxxxxxxx (pneumokoka) Xxxxxxxxxxxxx xxxxxxxxxx sérotypu 23X&xxxx;1,2&xxxx;2,2 μg
polysacharid bakterie (xxxxxxxxxx) Xxxxxxxxxxxxx pneumoniae xxxxxxxx 33X&xxxx;1,2&xxxx;2,2 μx
1 Xxxxxxxxxx x xxxxxx xxxxxxxxx XXX197&xxxx;(xxxxxxxxx 51 μx xx xxxxx)
2 Xxxxxxxxxx xx xxxxxxxxxxx xxxxxxx (0,125 xx xxxxxxx xx dávku)
1i) očkovací xxxxx xxxxx záškrtu, xxxxxxxx xxxxx (xxxxxxxxxx xxxxx), xxxxxx, dětské xxxxxxxx obrně (xxxxxxxxxxxx xxxxx):
Xxxxx xxxxx (0,5 xx) xxxxxxxx:
Xxxxxxxxxxx xxxxxxxxxx1&xxxx;- xx méně než 2 mezinárodní jednotky (XX) (2,5 Xx)
Xxxxxx xxxxxxxxxx1&xxxx;- xx xxxx xxx 20 xxxxxxxxxxxxx xxxxxxxx (IU) (5 Xx)
Xxxxxxxxxxx pertussis xxxxxxxx:
Xxxxxxxxx xxxxxxxxxx1-&xxxx;8 xxxxxxxxxx
Xxxxxxxxx haemagglutinum xxxxxxxxxxxx1&xxxx;- 8 xxxxxxxxxx
Xxxxxxxxx1&xxxx;2,5 xxxxxxxxxx
Xxxxx poliomyelitidis inactivatum:
ty xxx 1 (xxxx Xxxxxxx)2&xxxx;- 40 X xxxxxxxx antigenu
typus 2 (xxxx XXX-1)2&xxxx;- 8 X xxxxxxxx xxxxxxxx
xxxxx 3 (xxxx Xxxxxxx)2&xxxx;- 32 X jednotek xxxxxxxx
1 xxxxxxxxxxx xx xxxxxxxxxxx xxxxxxxx xxxxxxx (Xx(XX)3) 0,3 xxxxxxxxx Xx3+&xxxx;x xxxxxxxxxxx xxxxxxx (XxXX4) 0,2 xxxxxxxxx Xx3+
2 pomnoženo na XXXX xxxxxxx
XXXX
1xx)&xxxx;xxxxxxxx xxxxx xxxxx xxxxxxx, xxxxxxxx xxxxx (xxxxxxxxxx forma), xxxxxx, xxxxxx přenosné xxxxx (xxxxxxxxxxxx xxxxx):
Xxxxx xxxxx (0,5 xx) xxxxxxxx:
Xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx 2 XX* (2,5 Xx)
Xxxxxx xxxxxxxxxx xxxxxxxxx 20 XX* (5 Xx)
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxx xxxxxxxxxx 2,5 xxxxxxxxxx
Xxxxxxxxx haemagglutininum xxxxxxxxxxxx 5 mikrogramů
Pertactinum 3 mikrogramy
Fimbriae, xxxx 2 xx 3 5 mikrogramů
Virus xxxxxxxxxxxxxxx (xxxxxxxxxxx)**
xxxxx 1 40 X xxxxxxxx antigenu
ty xxx 2 8 X xxxxxxxx xxxxxxxx
xxxxx 3 32 D xxxxxxxx antigenu
Adsorbováno na xxxxxxxxxxx hlinitý 1,5 xx (0,33 xx xxxxxxx)
*&xxxx;Xxxx spodní xxxxxxx xxxxxxxxx xxxxxxxxxxxxx (x = 0,95) xxxxxxxx xxxxxx podle xxxxx xxxxxxxxx v Xxxxxxxxx xxxxxxxx.
**&xxxx;Xxxxxxxxxxx na Vero xxxxxxx.
1x)&xxxx;xxxxxxxx xxxxx proti xxxxxxxxxxx (XXX xxxxxxx)
1x)&xxxx;xxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxxxx B xxx xxxxx xxxxxxxx xx xxxxxxxxxxxx programu:
Jedna xxxxx (0,5 ml) xxxxxxx xxxxxxxx:
Xxxxxxxxx xxxxxxxxx xxxxxxxxxxx X1,2,3&xxxx;- 20 xxxxxxxxxx
1 xxxxxxxxxx xx XX04X xxxxxxxxxx: - 3-O-deacyl-4'-monofosforyl-lipid X (XXX)2&xxxx;50 xxxxxxxxxx
2 xxxxxxxxxxx na xxxxxxxxxxx xxxxxxx (celkem 0,5 xxxxxxxxx Al3+)
3 vyrobeno xx xxxxxxx kvasinkových xxxxx (Xxxxxxxxxxxxx xxxxxxxxxx) xxxxxxxxxxxxx XXX xxxxxxxxxxx.
2.&xxxx;Xxxxxxxxx xxxxxxx xxxxxxxxxx látek xxx xxxxxxxx xxxxxxxx
2x)&xxxx;xxxxxxxx xxxxx xxxxx virové xxxxxxxxxx X ve xxxxxxx xxx dospělé:
Jedna xxxxx obsahuje:
Antigenum xxxxxxxxx xxxxxxxxxxx B - 20 xxxxxxxxxx
2x)&xxxx;xxxxxxxx látka xxxxx xxxxxxxxx
2x)&xxxx;xxxxxxxx xxxxx xxxxx xxxxxx hepatitidě X xx xxxxxxx xxx xxxxxxx:
Xxxxx dávka xxxxxxxx:
Xxxxxxxxx X xxxxx xxxxxxxxxxx
2x)&xxxx;xxxxxxxx xxxxx xxxxx xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxx:
Xxxxx dávka xxxxxxxx:
Xxxxxxxxxxx xxxxx xxxxxxxxxx1&xxxx;(Xxxxxxx) xxx. 103,0&xxxx;xxxxxxxx dávka xxx xxxxxxxx xxxxxxx503
Xxxxxxxxxxx virus xxxxxxxxxx1&xxxx;(XXX 4385) min. 103,7&xxxx;xxxxxxxx xxxxx xxx xxxxxxxx xxxxxxx503
Xxxxxxxx xxxxx xxxxxxxxxx2&xxxx;(Xxxxxx XX 27/3) xxx. 103,0 infekční xxxxx xxx xxxxxxxx kulturu503
1 pomnoženo xx buňkách kuřecích xxxxxx
2&xxxx;xxxxxxxxx na xxxxxxxx xxxxxxxxxxx xxxxxxx (XXX-5)
3&xxxx;50% xxxxxxxx xxxxx xxxxxxx xxxxxxx
XXXX
2xx)&xxxx;xxxxxxxx xxxxx proti xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxx
Xx xxxxxxxxxx xxxxxxxx xxxxx xxxxx (0,5 xx):
Xxxxx xxxxxxxxxxx1&xxxx;xxxxx xxxxxxxxxx (xxxx Enders’ Edmonston) xx xxxx než 1x103&xxxx;XXXX50*
Xxxxx xxxxxxxxxxx1&xxxx;xxxxx attenuatum (xxxx Xxxxx Lynn™, xxxxxxx X) ne xxxx xxx 12,5x103&xxxx;XXXX50*
Xxxxx xxxxxxxx2&xxxx;xxxxx xxxxxxxxxx (xxxx Xxxxxx XX 27/3) xx méně xxx 1x103&xxxx;XXXX50*
*&xxxx;50% infekční dávka xxxxxxx xxxxxxx
1&xxxx;xxxxxxxx na xxxxxxx xxxxxxxx embryí.
2 vyrobeno xx xxxxxxxx xxxxxxxxxxx xxxxxxxx WI-38 xxxxxxxxxxxxx.
3.&xxxx;Xxxxxxxxx xxxxxxx xxxxxxxxxx látek xxx mimořádná xxxxxxxx
3x)&xxxx;xxxxxxxx xxxxx xxxxx virové xxxxxxxxxx A xx xxxxxxx pro xxxxxxx:
Xxxxx xxxxxxxxx X xxxxxxxxxxx
3x)&xxxx;xxxxxxxx xxxxx xxxxx virové xxxxxxxxxx A ve xxxxxxx xxx xxxx:
Xxxxx xxxxxxxxx X inactivatum
3c) očkovací xxxxx xxxxx spalničkám, xxxxxxxxxx x zarděnkám:
Jedna xxxxx obsahuje:
Morbillorum xxxxx xxxxxxxxxx1&xxxx;(Xxxxxxx) xxx. 103,0 infekční xxxxx pro buněčnou xxxxxxx503
Xxxxxxxxxxx virus xxxxxxxxxx1&xxxx;(XXX 4385) xxx. 103,7&xxxx;xxxxxxxx xxxxx pro xxxxxxxx xxxxxxx503
Xxxxxxxx virus attenuatum2 (Wistar XX 27/3) min. 103,0&xxxx;xxxxxxxx xxxxx xxx xxxxxxxx xxxxxxx503
1&xxxx;xxxxxxxxx na xxxxxxx xxxxxxxx xxxxxx
2&xxxx;xxxxxxxxx xx lidských diploidních xxxxxxx (MRC-5)
3 50% infekční xxxxx tkáňové xxxxxxx
XXXX
3xx)&xxxx;xxxxxxxx xxxxx xxxxx spalničkám, xxxxxxxxxx x xxxxxxxxx
Xx xxxxxxxxxx xxxxxxxx xxxxx xxxxx (0,5 ml):
Virus xxxxxxxxxxx1&xxxx;xxxxx attenuatum (kmen Xxxxxx’ Xxxxxxxxx) xx xxxx než 1x103 CCID50*
Virus xxxxxxxxxxx1&xxxx;xxxxx xxxxxxxxxx (xxxx Xxxxx Lynn™, xxxxxxx X) xx xxxx xxx 12,5x103 CCID50*
Virus xxxxxxxx2&xxxx;xxxxx xxxxxxxxxx (xxxx Wistar XX 27/3) ne xxxx než 1x1 103&xxxx;XXXX50*
*&xxxx;50% infekční xxxxx xxxxxxx xxxxxxx
1&xxxx;xxxxxxxx na xxxxxxx xxxxxxxx xxxxxx.
2&xxxx;xxxxxxxx xx xxxxxxxx diploidních xxxxxxxx WI-38 fibroblastech.
Ministr:
prof. XXXx. Xxxxx, XXx, XXX, EBIR, v. x.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 420/2023 Xx. nabyl xxxxxxxxx xxxx 29.12.2023.
Xx xxx uzávěrky xxxxxx xxxxxxx nebyl xxxxx xx xxxxxxxxx.
Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného právního xxxxxxxx.